At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 32 enrolled
Drug / intervention
R0.6C transmission blocking vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety, Tolerability and Plasmodium Falciparum Transmission-reducing Activity of R0.6C Vaccine Adjuvanted With Alhydrogel Alone or Combined With Matrix-M in Healthy Malaria-naïve Adults in the Netherlands
In Brief
A Phase 1 clinical trial evaluating R0.6C transmission blocking vaccine for Malaria and Malaria,Falciparum. Completed, enrolled 32 participants across 1 site.
Detailed Summary
This is a first-in-human phase I, open-label, single-site, dose escalation study to determine the safety, tolerability and Plasmodium falciparum transmission reducing activity of the R0.6C vaccine in two different adjuvant combinations.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalaria, Malaria,Falciparum
CountriesNetherlands
CollaboratorsStatens Serum Institut, Novavax
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedApr 2021
Enrollment StartMay 2021
Primary CompletionJun 2022
TodayJul 2026
First PostedApr 28, 2021
Enrollment StartMay 17, 2021
Primary CompletionJun 29, 2022
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 5.2 years ago
Interventions
R0.6C transmission blocking vaccinebiological
Vaccination with R0.6C transmission blocking vaccine. Volunteers will sequentially receive four administrations of R0.6C intramuscularly in the deltoid muscle on alternating sides on days 0, 28, 56 and 168.